Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial
Loading...
Identifiers
Publication date
Authors
Blanco Vich, Isabel
Fernández Friera, Leticia
Prat González, Susanna
Jordà, Paloma
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF].
Description
UNESCO Subjects
Keywords
Bibliographic reference
García Lunar, I., Blanco Vich, I., Fernández Friera, L., Prat Gonzàlez, S., Jordà, P., Sánchez, J., Pereda, D., Pujadas, S., Rivas Lasarte, M., Solé González, E., Vázquez, J., Blázquez, Z., García Picart, J., Caravaca, P., Escalera, N., García Pavia, P., Delgado, J., Segovia Cubero, J., Fuster, V., … García Álvarez, A. (2020). Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial. JACC: Basic to Translational Science, 5(4), 317-327. https://doi.org/10.1016/j.jacbts.2020.01.009
Type of document
Collections
La licencia de este ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional